P
hysical and innate immune barriers serve to make mucosal transmission of HIV-1 a relatively inefficient process. As a result, establishment of virus infection in a naïve host most often results from the transmission and subsequent propagation of a single virus strain, termed a transmitted/founder (T/F) virus (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Virologic traits that might enable a virus to overcome one or more of these barriers could be selected for during transmission, and identification of such traits should lead to a greater understanding of the earliest events in HIV-1 infection and could suggest new prevention strategies.
Single genome amplification has enabled the inference of a large number of T/F env's from multiple virus clades (2, (11) (12) (13) (14) (15) . This has made it possible to seek genotypic and phenotypic differences between T/F Env proteins and those derived from chronically infected individuals (chronic control [CC] Envs). Several phenotypic characteristics are clearly associated with transmission: T/F Envs virtually always use CCR5 rather than CXCR4 or other noncanonical coreceptors (2, (16) (17) (18) and generally infect T cells but not macrophages (2, 13, 15, 19) as a result of requiring relatively high levels of CD4 to mediate virus entry (20) (21) (22) (23) (24) (25) . Other phenotypic and genotypic traits that have been linked to transmission are less well defined: Envs isolated from acute infection have sometimes been reported to be more neutralization sensitive (19) , have on average fewer putative N-linked glycosylation sites (1, 26) , and have shorter variable loops (1, (27) (28) (29) compared to Envs isolated from chronically infected individuals.
Recently, Swanstrom and colleagues reported an additional phenotypic difference between clade C T/F and CC Env proteins (30) . They found that CC Envs were more likely than T/F Envs to exhibit partial resistance to the CCR5 antagonist maraviroc (MVC) on 293T cells expressing high levels of CCR5, but not on 293T cells expressing lower levels of CCR5. This finding suggests that CC Envs are often capable of infecting cells by using the MVC-bound conformation of CCR5 or that they are able to utilize a form of CCR5 that is unable to bind MVC. However, our work and that of others have not revealed differences in MVC sensitivity between T/F and CC Envs on an NP2 cell line (19, (31) (32) (33) .
To reconcile these findings, we examined a previously described panel of clade B and clade C Env proteins from T/F and CC viruses (19, 31) for their ability to infect cell lines and primary human CD4 ϩ T cells in the presence of saturating concentrations of MVC. On 293T cells expressing high levels of CCR5, we confirmed that clade C CC Envs were much more likely than T/F Envs to mediate infection in the presence of MVC as shown by Swanstrom and colleagues (30) . We found this property to be shared by clade B Envs and extended these observations further to include cell lines expressing 5-to 10-fold-lower levels of CCR5 and on primary human CD4 ϩ T cells. Subtle differences in the efficiency with which MVC inhibited infection of 87 different T/F and CC viruses on cells expressing low levels of CCR5 was highly predictive of more overt MVC resistance when CCR5 expression levels were high. This property was also seen with other CCR5 antagonists, with replication-competent infectious molecular clones (IMCs), and did not correlate with other phenotypic properties.
Since the efficiency of virus entry in the presence of MVC increased with CCR5 expression levels, we conclude that many CC Envs can utilize at least some of the drug-bound conformations of CCR5, albeit inefficiently. Nonetheless, the differential ability of clade B and C T/F and CC Envs to use MVC-bound CCR5 argues that the more promiscuous use of CCR5 conformations by many chronic viral Env proteins is selected against at the level of virus transmission by a mechanism(s) that has not yet been elucidated by in vitro assays but is selected for during chronic infection. Differences in the populations of CD4 ϩ CCR5 ϩ cells that are targeted by HIV in acute versus chronic infection may reveal differences in how T/F and CC Envs mediate virus infection and could suggest new prevention strategies.
MATERIALS AND METHODS

Description of Envs and IMCs.
The derivations of all the Env clones and infectious molecular clones (IMCs) used in this study have been described previously (2, 13, 19, 31) . Briefly, the sequences of all Envs and IMCs were inferred from single genome sequencing of acute or chronically infected donors. The Envs or IMCs were then amplified from the first-round PCR product or gene synthesized and then subcloned into pCDNA3.1 ϩ directional TOPO or pCRXL TOPO vector (Invitrogen). Clade B CC Envs were randomly selected among sequences from the chronic swarm that were predicted to be functional, while clade C CC Envs were generated by determining the most recent common ancestor of discrete clonally expanded populations, evident as minor populations in phylogenetic trees of chronic sequences (31) . A summary of the geographic origin and infection status for Envs and IMCs is shown in Table S1 in the supplemental material.
Cell culture. 293T17, 293T-derived Affinofile, NP2/CD4/CCR5, NP2/ CD4/CXCR4, and U87/CD4 cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% (vol/vol) fetal bovine serum (FBS) (Sigma-Aldrich) and 1% penicillin-streptomycin. Affinofile cells were maintained in DMEM supplemented with 10% FBS, 1% penicillinstreptomycin per ml, 50 g/ml blasticidin per ml, and 200 g/ml G418 per ml.
Pseudovirus production and normalization. HIV-1 Env pseudoviruses were produced by calcium phosphate cotransfection of 6 g of pcDNA3.1 ϩ containing the desired env clone with 10 g of HIV-1 core (pNL43-⌬Env-vpr ϩ -luc ϩ or pNL43-⌬Env-vpr ϩ -eGFP) into 293T17 cells. At 72 h posttransfection, the pseudovirus-containing supernatant was harvested and filtered through a 0.45-m-pore-size filter, aliquoted, and stored at Ϫ80°C. For primary CD4 ϩ T cell infections, pseudovirus was concentrated approximately 100-fold by ultracentrifugation at 113,000 ϫ g for 2 h at 4°C through a 20% sucrose cushion. Pelleted pseudovirus was then resuspended in phosphate-buffered saline (PBS). All luciferase-encoding pseudoviral stocks were serially diluted on NP2/CD4/ CCR5 cells to define the linear range of the assay. Relative light units (RLUs) of all viruses used were well within the 5-log linear range of the assay.
Virus inhibition assays. The HEK293T-based CD4/CCR5 dual-inducible cell line (Affinofile) was employed to assess the sensitivity of pseudovirions and replication-competent viruses to CCR5 antagonists at different levels of CCR5 surface expressions. CD4 expression was induced with minocycline, and CCR5 expression was induced with ponasterone A (Pon A) as described previously (34) . Briefly, 650 cells were plated in each well of a 96-well plate and then 48 h later they were induced with a final concentration of 10 ng/ml minocycline to maximally express CD4 and either 2 M or 0.031 M Pon A to express high and low CCR5, respectively. Eighteen hours postinduction, CD4 and CCR5 expression levels were determined by quantitative flow cytometry (BD QuantiBrite) as described below. Induced Affinofile cells or NP2/CD4/CCR5 or U87/CD4 cells transiently transfected with pcDNA3.1 ϩ encoding CCR5 using Lipofectamine 2000 (Invitrogen) were used for CCR5 antagonist inhibition studies. Cells were preincubated for 30 min at 37°C with either 2 M drug, previously shown to be saturating (57), or 3-fold serial dilutions from 6 M to 0.1 M the CCR5 antagonists maraviroc (MVC), aplaviroc (APL), CMPD-167, TAK-779, vicriviroc (VVC), or medium alone prior to infection with the indicated luciferase reporter pseudovirus. After addition of pseudovirus, plates were spinoculated at 450 ϫ g for 2 h at 4°C and then incubated at 37°C. We also performed experiments without spinoculation and obtained similar results: spinoculation increased infection by approximately 2-fold, but did not impact the sensitivity of viruses to maraviroc. Cells were lysed with Brite-Glo (Promega) at 72 h postinfection, and relative light units (RLUs) were assessed on a Luminoskan Ascent luminometer. All inhibition assays were done in triplicate in each of at least two independent experiments using an MVC-sensitive and partially MVCresistant R5-tropic Env as controls.
Primary human CD4 ؉ T cell infections. Primary human CD4 ϩ T cells, purified by negative selection, were obtained from the Human Immunology Core of the University of Pennsylvania's Center for AIDS Research (CFAR). Cells were infected as described previously (19) . Briefly, 1.5 ϫ 10 6 cells per condition were stimulated with plate-bound anti-CD3 (clone OKT3; eBiosciences) and anti-CD28 (clone 28.2; BD Biosciences) and 20 U/ml recombinant interleukin-2 (IL-2; Aldesleukin) in RPMI medium containing 10% FBS. Three days poststimulation, cells were transferred to 96-well V-bottom plates and incubated for 30 min with 6 M MVC or a no-drug control. Approximately 5 g p24 of concentrated HIV-green fluorescent protein (GFP) pseudovirus was used to infect cells in triplicate in a total volume of 50 l at a cell concentration of 1 ϫ 10 7 cells/ml. Plates were then spinoculated at 1,200 ϫ g for 2 h at 4°C. Cells were resuspended at 1 ϫ 10 6 cells/ml. Three days postinfection, cells were stained with live/dead aqua (1 l) (Invitrogen), anti-CD4 Alexa Fluor 700 (2 l) (Invitrogen), and anti-CD3 Qdot 655 (0.5 l) (Invitrogen) and examined by flow cytometry, and the fraction of cells that were GFP positive were determined. HIV-infected cells were defined as live/dead CD3 ϩ
CD4
Ϫ GFP ϩ as cell surface CD4 is downregulated upon infection. Flow cytometry. Cell staining was performed at room temperature in 50 l fluorescence-activated cell sorter (FACS) wash buffer (PBS, 2.5% FBS, 2 mM EDTA). For CD4 ϩ T cells, cells were first washed in PBS, and then live/dead aqua (Invitrogen) was added and incubated for 10 min. Quantitative FACS. Quantitative FACS was performed to convert mean fluorescence intensity (MFI) into antibody binding sites (ABS) by using a standardized microbead kit (BD Biosciences) according to the manufacturer's instructions. The MFI of the isotype control for each experiment was converted to ABS and subtracted from the ABS value obtained with the experimental sample.
Statistical and correlation analyses. Infection values obtained with T/F and chronic Env pseudovirions were compared using Mann-Whitney tests, Fisher's exact tests, or t tests, and correlations were assessed using Spearman's tests. P values of less than 0.05 were considered significant. Data were analyzed with Prism 5.0 software.
Ethics statement.
All human cells used in this study were from normal healthy donors who provided written informed consent after approval by the University of Pennsylvania's Institutional Review Board.
RESULTS
Partial resistance to MVC on Affinofile cells with high-CCR5
surface expression. Swanstrom and colleagues observed that chronic clade C Envs mediate low levels of infection on Affinofile cells expressing high levels of CCR5 in the presence of MVC more frequently than T/F Envs. To assess if an independent panel of 87 clade B and C Envs (19, 31) would recapitulate this finding, we also utilized the 293T-derived Affinofile cell system. Among these pseudoviruses were 24 clade B and 16 clade C T/F Envs, as well as 28 clade B and 19 clade C CC Envs, all derived by single-genome amplification and described in earlier reports (2, 19, 31) . The Affinofile cell line makes it possible to independently modulate surface expression of CD4 and CCR5 by applying different concentrations of the transcriptional activators minocycline and Pon A, respectively (34) .We examined the sensitivity of HIV-1 Env pseudoviruses to MVC on Affinofile cells expressing relatively low or high levels of CCR5 (low-or high-CCR5 Affinofile cells), while maximally inducing CD4 levels. PonA treatment increased the overall expression of CCR5 on Affinofile cells from 2,723 (uninduced) to 23,470 (high induction) antibody binding sites (ABS) per cell (Fig. 1A) . To confirm that 6 M MVC was saturating at the highest level of CCR5 expression, we assessed the difference in residual infection between the two highest concentrations of MVC employed and found that there was no increase in inhibition of infection from 2 M to 6 M MVC, indicating that 2 M was saturating and that further increases in drug did not have any additional inhibitory effect (P ϭ 0.70 by paired t test) (Fig. 1B) .
Affinofile cells expressing low or high levels of CCR5 were infected by each of the 87 pseudoviruses in the presence or absence of increasing concentrations (to a maximum of 6 M) of MVC, after which we calculated the maximal percent inhibition (MPI). We imposed an arbitrary MPI cutoff of 95%, where MPI values of Ͼ95% were considered MVC sensitive, while samples with MPI values less than or equal to 95% were assumed to be partially resistant to MVC. We found that infection by all 87 pseudoviruses was inhibited by Ͼ95% at saturating concentrations of MVC on low-CCR5 Affinofile and NP2/CD4/CCR5 cells, consistent with our previous results (19, 31) . On high-CCR5 Affinofile cells, 57 of 87 (66%) of the pseudoviruses were inhibited by MVC by Ͼ95% (Fig. 1C , representative pseudovirus is shown in the top panel), while 30 of 87 (34%) of the pseudoviruses exhibited partial resistance defined by an MPI of Յ95% in the presence of 6 M MVC, with some pseudoviruses exhibiting considerable MVC resistance (MPI values as low as 60%) (Fig. 1C, middle panel) . JRFL, which is MVC sensitive, was included as a control in all experiments (Fig. 1C, bottom panel) . When CCR5 levels were high, the amount of MVC needed to achieve maximal inhibition increased for all viruses as expected. These results confirmed a central finding of Swanstrom and colleagues (30) , in that a considerable number of viruses do indeed exhibit a reduced MPI when MVC is used to inhibit infection on high-CCR5 Affinofile cells.
Partial MVC resistance is enriched in chronic HIV-1 but is not clade or antagonist specific. There was a striking difference in the frequency with which T/F and CC Envs exhibited partial MVC resistance (15% [6 of 40] versus 52% [24 of 47] ; P Ͻ 0.0001 by Fisher's exact test) ( Fig. 2A) . This partial resistance was not clade specific, as 50% (14 of 28) of clade B and 53% (10 of 19) of clade C CC Envs exhibited partial resistance to MVC, whereas only 17% (4 of 24) of clade B and 13% (2 of 16) of clade C T/F Envs exhibited this property under conditions of high-CCR5 expression (clade B, P ϭ 0.02, and clade C, P ϭ 0.02, by Fisher's exact test) (Fig. 2B) . Not only was the distribution of MVC-sensitive and -resistant Envs similar for clade B and C pseudoviruses, but these distributions were similar to those reported by Swanstrom and colleagues with their panel of clade C Envs (30) . Thus, partial resistance to MVC on cells expressing high levels of CCR5 is reproducible and is not clade specific.
To assess if MVC resistance predicted resistance to other CCR5 antagonists, we evaluated the sensitivity of four partially MVCresistant pseudoviruses to four additional small molecule CCR5 inhibitors: aplaviroc, CMPD-167, TAK-779, and VVC. Similar to the results with MVC, all four pseudoviruses tested were inhibited by Ͼ95% by all CCR5 antagonists on Affinofile cells expressing low levels of the coreceptor. However, at high CCR5 surface expression, all four pseudoviruses were partially resistant to the other CCR5 antagonists, similar to the results obtained with MVC (representative results are shown in Fig. 2C ). Furthermore, the residual infection seen at high levels of CCR5 on Affinofile cells in the presence of CCR5 antagonists was not due to the use of low endogenous levels of CXCR4 present on 293T cells, as the addition of the CXCR4 inhibitor AMD3100 did not affect the MPI of partially resistant pseudoviruses (data not shown). Finally, we tested four IMCs whose Env proteins had been tested as part of the pseudovirus panel, including two T/F IMCs that were sensitive to MVC on high-CCR5 Affinofile cells and two CC IMCs that exhibited partial MVC resistance. The results with the replication-competent viruses mirrored the results obtained with the respective pseudoviruses (data not shown), indicating that the partial resistance phenotype observed under conditions of high CCR5 is not an artifact of the pseudotyping system. Taken together, these results suggest that clade C and B CC Envs exhibit partial resistance to CCR5 antagonists at high levels of CCR5 much more frequently than T/F Envs.
MVC sensitivity on cells expressing low levels of CCR5 predicts MVC resistance on cells expressing high levels of CCR5. We previously reported that T/F and CC Env pseudovirus infection of NP2/CD4/CCR5 cells expressing CD4 and CCR5 were equally sensitive to MVC, exhibiting similar 50% inhibitory concentrations (IC 50 ). In addition, all T/F and CC Envs were inhibited by saturating concentrations of MVC by Ͼ95% (19, 31) . However, dose-response curves with different slopes can appear similar on traditional semilog plots, masking differences in maximal inhibition (35, 36) . Therefore, we performed new infection assays using the entire panel of viruses on NP2/CD4/CCR5 cells, which stably express intermediate levels of CCR5 (Fig. 1A) , and compared the results to those obtained on low-CCR5 and high-CCR5 Affinofile cells by plotting the residual infection for each virus on a log scale (Fig. 3) . While MVC inhibited all pseudoviruses by Ͼ95% on both low-CCR5 Affinofile and NP2/CD4/CCR5 cells, there was considerable variability in residual infection values for different T/F and CC Env pseudotypes. On NP2/CD4/CCR5 cells, there was a significant difference in median residual infection between T/F and CC Envs (T/F median, 0.06%; chronic median, 0.15%; P ϭ 0.01 by Mann-Whitney test). The magnitude of this difference was more pronounced on high-CCR5 Affinofile cells (T/F median, 0.54%; chronic median, 4.8%; P ϭ 0.0003 by Mann-Whitney test) but was not apparent on low-CCR5 Affinofile cells (T/F median, 0.18%, chronic median, 0.14%; P ϭ 0.94 by MannWhitney test). When we reexamined the NP2/CD4/CCR5 infection data from our previous studies (19, 31) , the same correlations were observed.
Are the low and variable levels of infection on low-CCR5 Affinofile and NP2/CD4/CCR5 cells in the presence of MVC predictive of more efficient infection in the presence of MVC when CCR5 levels are high? To determine this, we plotted residual infection on low-CCR5 Affinofile (Fig. 4A ) or NP2/CD4/CCR5 cells ( MVC. We found a moderate correlation between these values when comparing low-CCR5 Affinofile and high-CCR5 Affinofile cells (Spearman's correlation coefficient ϭ 0.22; P ϭ 0.04) (Fig. 4A ) and a more significant correlation when comparing NP2/CD4/CCR5 to high-CCR5 Affinofile cells (Spearman's correlation coefficient ϭ 0.65; P Ͻ 0.0001) (Fig. 4B) . These results argue that an appreciable number of CC Envs can utilize MVCbound CCR5 but that this ability is less obvious on cells expressing low to moderate levels of CCR5, unless results are plotted on a log scale. When this is done, small differences in residual virus infection are not only evident but highly predictive of substantive infection when CCR5 expression levels are high. To further confirm this finding, we examined a subset (4 T/F and 8 CC Envs) of our pseudoviruses on U87/CD4 cells in which CCR5 was transiently expressed, resulting in high levels of CCR5 (Fig. 1A) . These experiments recapitulated our findings on high-CCR5 Affinofile cells: viruses that exhibited MPIs of Ͻ95% on high-CCR5 Affinofile cells likewise exhibited reduced MPIs on transiently transfected U87/CD4 cells, while viruses that remained highly sensitive to MVC under these conditions were likewise efficiently inhibited on CCR5-expressing U87/CD4 cells (data not shown).
Utilization of CCR5 in the presence of MVC is evident on primary human CD4
؉ T cells. To assess whether this phenotype is recapitulated under more physiologically relevant conditions, we infected primary human CD4 ϩ T cells with GFP-expressing Env pseudoviruses in the presence or absence of saturating concentrations of MVC. To maximize the sensitivity of this primary cell assay, we selected three T/F pseudoviruses that were efficiently inhibited by MVC on high-CCR5 Affinofile cells and three CC pseudoviruses that exhibited significant resistance to MVC under these conditions. Peripheral blood CD4 ϩ T cells from two uninfected donors, in each of two independent experiments, were purified by negative selection and stimulated with plate-bound anti-CD3/anti-CD28 and IL-2 for 3 days. Cells were incubated in the presence or absence of saturating levels of MVC (6 M) 30 min prior to infection. Three days postinfection, cells were analyzed by flow cytometry and infected cells were determined by gating on live CD3 ϩ CD4 Ϫ GFP ϩ events. We found that the three CC pseu- doviruses exhibited significant residual infection compared to T/Fs on CD4 ϩ lymphocytes in the presence of saturating MVC (P ϭ 0.04 by t test) (Fig. 5) . Further, these differences reflected those previously observed for these viruses on high-CCR5 Affinofile cells and on NP2/CD4/CCR5 cells (Fig. 5 ). The differences were most pronounced on high-CCR5 Affinofile cells (which express the highest levels of CCR5), less pronounced on NP2/CD4/ CCR5 cells (intermediate levels of CCR5), and the least pronounced (but still observable) on primary CD4 ϩ T cells (low levels of CCR5). Thus, these results are again consistent with the hypothesis that many CC Envs can utilize MVC-bound CCR5 and that high levels of CCR5 magnify this property, revealing differences in how T/F and CC Envs engage this coreceptor.
Ability to use MVC-bound CCR5 is not related to overall level of infectivity or other viral phenotypes. The ability of some HIV-1 strains to recognize MVC-bound CCR5 has been linked to differences in how the Env protein engages its chemokine coreceptor (37) (38) (39) . As a result, it is possible that the striking difference in the frequencies with which T/F and CC viruses mediate infection in the presence of MVC, albeit inefficiently at physiologic levels of CCR5 expression, is a surrogate measure for some other phenotypic property. In two previous studies, we tested these clade B and C pseudoviruses in a variety of phenotypic assays, comparing T/F to CC Envs (19, 31) . With the exception of some clade-specific neutralization sensitivity, no significant genotypic or phenotypic differences were identified. In light of our current findings, we reanalyzed these data, comparing Envs that were partially resistant to MVC on high-CCR5 Affinofile cells to 18 previously determined Env properties ( Table 1) . None of the pheno- 
FIG 5 CC Envs exhibit greater residual infection compared to T/F Envs on primary human CD4
ϩ T cells. Levels of residual infection for three T/F (black) and three CC (gray) Envs on CD4 ϩ T cells were assessed in the presence of saturating MVC. Higher levels of residual infection were mediated by CC Envs in the presence of MVC than to T/F Envs (CC median, 1.1%, versus T/F median, 0.51%; P ϭ 0.10). Residual infection for the three T/F and CC Envs were compared between CD4 ϩ T cells, high-CCR5 Affinofile cells, and NP2/ CD4/CCR5 cells. In all three cell types, CC Envs displayed higher residual infection than T/F Envs. All primary cell infections were done with at least two donors in triplicate in at least two independent experiments. typic characteristics previously measured for these panels correlated strongly with incomplete inhibition by MVC, including CD4 use efficiency, neutralization by monoclonal antibodies (MAbs; b12, VRC01, PG9, and PG16) or by pooled sera from patients infected with either clade B or C HIV-1 strains (clade B/C HIV Ig), or primary CD4 ϩ T cell subset tropism. Except for V5 length, we found no strong genetic correlates of incomplete MVC inhibition, including V1-V4 individual and total variable loop lengths and potential N-linked glycosylation sites. We also asked whether the ability to utilize CCR5 in the presence of MVC was simply a property of highly functional Env proteins or highly infectious Env pseudoviruses. To address this, we plotted pseudoviral infectivity (RLU) in the absence of MVC against residual infection at saturating concentrations of MVC. There was no correlation between overall infectivity and the partial resistance phenotype (Spearman's correlation coefficient ϭ 0.02; P ϭ 0.84) (Fig. 6) . Therefore, residual infection was not a surrogate measure for increased infectivity.
DISCUSSION
In addition to using CCR5 and being T-cell tropic, several other phenotypic and genotypic traits have been associated with T/F Env proteins relative to those from chronic viruses (1, 2, 12, 13, 19,  27-29, 31 ). Among these, the differential utilization of CCR5 first observed by Swanstrom and colleagues, confirmed and extended here, is arguably the most robust. Both clade B and C T/F Envs are far more likely to be inhibited in entry by MVC on cells expressing high levels of CCR5 than are CC Envs. The ability of many CC Envs to mediate infection in the presence of MVC under conditions where CCR5 expression levels are high indicates that these Envs can utilize one or more conformations of CCR5 better than most T/F Envs. This suggests that there is selective pressure against the more promiscuous CCR5 utilization phenotype exhibited by many CC Envs at the level of HIV transmission and selection for this trait during chronic infection. Questions that remain to be addressed are the mechanism that underlie this phenotype, whether genetic signatures associated with differential use of CCR5 can be identified, and whether this phenotype observed on a cell line expressing levels of CCR5 that greatly exceed those seen on primary cells is a correlate for another property that would be more meaningful at the level of mucosal transmission of HIV-1.
MVC is a CCR5 antagonist that potently inhibits infection by virtually all R5 strains of HIV-1 in vitro (40) , blocks vaginal transmission of SHIV-162P3 in a rhesus macaque model (41) , and significantly diminishes virus loads in HIV-1-infected individuals (42) . Clearly, MVC is an effective inhibitor of HIV infection under most experimental and clinical conditions. Thus, the finding by Swanstrom and colleagues that approximately one-half of CC Envs are inhibited less than 95% by MVC on 293T cells expressing high levels of CD4 and CCR5 was surprising. Here, we confirmed this finding using a large panel of clade C Envs and found that clade B Envs also exhibited this property to a similar magnitude.
What is the mechanism that underlies the differential effects of MVC on T/F versus CC HIV-1 Envs? CCR5 antagonists are allosteric inhibitors; upon binding to CCR5, they induce a conformation that is not recognized by most HIV-1 strains (43) (44) (45) (46) (47) (48) (49) . Thus, the ability of many chronic HIV-1 Envs to mediate some degree of infection in the presence of saturating concentrations of MVC could mean that under these conditions, a fraction of CCR5 molecules assume a conformation that is unable to bind MVC but can be utilized by many chronic Env proteins. If so, then CCR5 may exhibit enhanced conformational heterogeneity when expression levels are high relative to when expression levels are low, with one or more of these conformations not binding MVC or doing so only poorly. CCR5 and seven-transmembrane domain receptors in general can assume different conformations as a result of binding ligands or G proteins (50) (51) (52) (53) (54) , and CCR5 has been shown to exhibit antigenic heterogeneity (55) (56) (57) (58) . It is also possible that at high levels of CCR5 expression, posttranslational modifications such as sulfation of the N-terminal domain or coupling to G proteins could become saturated, resulting in conformational heterogeneity. Thus, our results could be explained by a model in which one such conformation fails to bind MVC or does so only poorly, with this conformation being recognized by a large subset of CC Envs but by only a small fraction of T/F Env proteins. When coupled with the fact that HIV-1 Env interactions with CCR5 are variable as judged by the differential effects that some mutations in CCR5 have on infection by diverse HIV-1 strains (32, 59) , it is certainly plausible that CCR5 conformation could be influenced by expression levels in a manner that preferentially allows infection by CC but not T/F viruses in the presence of MVC.
A second possible mechanism to account for the ability of some Envs to mediate infection in the presence of MVC when CCR5 levels are high is that these Envs can utilize the drug-bound conformation of CCR5 very inefficiently, such that under physiological levels of CCR5 expression, infection appears fully suppressed by MVC and by other CCR5 antagonists. Our data, as well as work by Gorry and colleagues (60) , clearly favor this interpretation. Typically, virus inhibition curves are plotted on a linear scale. However, if inhibition is plotted on a log scale and a highly reproducible and quantitative assay is used, different antiretroviral agents can be revealed to exhibit considerable variability in their abilities to maximally inhibit HIV-1 (35, 36) . When we examined the ability of MVC to inhibit HIV-1 infection on NP2/ CD4/CCR5 cells in this way, it became apparent that while some viruses were inhibited by 99.9%, others were inhibited by 99.0% or somewhat less. We found that these small, residual levels of infection were highly predictive of the ability of a virus to mediate appreciable levels of infection when both CCR5 and MVC levels are high. When a subset of viruses were tested on primary human CD4 ϩ T cells in this way, the same results were obtained: viruses that mediated obvious levels of infection on high-CCR5 cells in the presence of MVC were inhibited less efficiently than viruses that remained highly sensitive to MVC regardless of CCR5 expression levels. Roche et al. have also found that some Envs that appear fully sensitive to MVC on cells expressing low to moderate levels of CCR5 exhibit some degree of resistance when CCR5 levels are high (60) . Thus, we conclude that using a cell line that expresses high levels of CCR5 simply amplifies a phenotype that is already present on cells expressing lower levels of CCR5 that can be easily overlooked (19, 31) .
Given that some R5 HIV-1 strains can mediate readily detectable levels of infection in the presence of high levels of both CCR5 and MVC, can this information be used to predict clinical outcomes when MVC is used as part of an antiviral regimen? The most common mechanism that underlies clinical failure associated with MVC treatment is expansion of preexisting viral variants that utilize CXCR4 to mediate infection (48, (61) (62) (63) (64) (65) . Less commonly, mutations in the Env protein enable it to use MVC-bound CCR5, sometimes with impressive efficiency (32, 39) . The question is whether these clinical failures are associated with preexisting viruses that are not completely inhibited by MVC, with this property being clearly evident only when using cells that express high levels of CCR5. In fact, Roche et al. found that a viral Env predisposed to acquire high-level resistance to CCR5 antagonists exhibited a low-level ability to use MVC-bound CCR5 on cell lines expressing high levels of this coreceptor (60) . Whether this will be a general property of viral Envs from patients who fail MVC via this pathway is not known but could be examined by testing the ability of Envs from such individuals to infect high-CCR5 Affinofile cells in the presence of MVC.
The most important question resulting from this work is why the ability to use MVC-bound CCR5 is associated so clearly with CC but not T/F Envs. What results in the selection of this phenotype during the course of natural HIV-1 infection in the absence of MVC therapy, and what selects against this phenotype at the level of mucosal transmission? Clearly, the reason cannot have anything to do with MVC per se, as none of the patients from whom we derived Envs had been treated with MVC. Thus, the striking difference between CC and T/F Envs seen by Swanstrom and colleagues and in our study is likely a surrogate for some other viral property. In our previous studies, we compared the phenotypic properties of panels of T/F and geographically matched CC Envs (19, 31) . We reanalyzed these data, comparing Envs that were almost totally inhibited by MVC on high-CCR5 cells to those that were not regardless of whether they were CC or T/F Envs (Table  1) . These analyses failed to identify any cross-clade phenotypic differences between these two groups, including the ability to infect different CD4
ϩ T cell subsets, use alternative coreceptors, neutralization sensitivity, dependence upon CD4 levels, and the ability to be captured by dendritic cells (DCs) and transmitted to T cells. In addition, there were no obvious genetic signatures between the two groups, save for a correlation with V5 loop length, with longer V5 loops being correlated with reduced MPI on high-CCR5 Affinofile cells. While Swanstrom and colleagues found that slightly higher glycosylation was associated with the MVC-resistant phenotype (30) , this correlation was not evident in our panel of combined clade B and C Envs. Given the plasticity with which Envs can interact with their coreceptors and the multiple Env determinants that can influence CCR5 interactions (32, 59, (66) (67) (68) (69) (70) (71) (72) , this is perhaps not surprising: much larger numbers of Env clones and sequences may be needed to identify genetic characteristics that are consistently linked with the ability to utilize MVCbound CCR5. The more promiscuous utilization of CCR5 conformations by CC Envs may reflect selection pressures in chronic infection where neutralizing antibodies are abundant and certain populations of CD4 ϩ CCR5 ϩ cells have been diminished or otherwise altered by viral cytopathicity. Earlier studies have shown that R5 viruses can become increasingly resistant to entry inhibitors over time, consistent with alterations in CCR5 use (73) (74) (75) . More promiscuous utilization of CCR5 could expand viral tropism under these conditions, in contrast to de novo infection of naïve hosts where virus infection of a more homogeneous population of CD4 ϩ CCR5 ϩ cells could be favored. Further characterization of the CD4 ϩ CCR5 ϩ cells that are targeted during acute infection may reveal differences in the abilities of T/F and CC Env proteins to mediate virus entry and identify new approaches to prevention.
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